D
Sell
7/22/2024Upgraded
PharmaCorp Rx Inc. (PTN.V) was upgraded to D- from E on 7/22/2024 due to an increase in the total return index, growth index and valuation index. Operating cash flow increased 34.12% from -$213.1 to -$140.4, EBIT increased 5.84% from -$178.1 to -$167.7, and earnings per share increased from -$0.0078 to -$0.0074.
E
Sell
4/1/2024Downgrade
Proton Capital Corp. (PTNP.V) was downgraded to E from D- on 4/1/2024 due to a decline in the valuation index.
D
Sell
6/2/2023Upgraded
Proton Capital Corp. (PTNP.V) was upgraded to D- from E+ on 6/2/2023 due to an increase in the valuation index.
E
Sell
3/1/2023Upgraded
Proton Capital Corp. (PTNP.V) was upgraded to E+ from E on 3/1/2023 due to a major increase in the total return index and valuation index.
E
Sell
12/22/2022None
PharmaCorp Rx Inc. (PCRX.V) was downgraded to E from U on 12/22/2022.
